COLUMBUS, Ohio, Jan. 17, 2019 /PRNewswire/ -- CAS, a division of the American Chemical Society (ACS), announced today that AMRI, a leading global life sciences contract research, development and manufacturing organization with locations in North America, Europe and Asia, signed a 5-year agreement for SciFinder®. This investment ensures that all AMRI researchers globally will continue to have access to SciFinder. SciFinder gives AMRI's research team unlimited access to the most comprehensive collection of scientific content, expertly curated by CAS scientists, and powerful search functionality that helps them translate that information into innovative approaches.
"SciFinder is an important tool for our researchers, providing ready access to scientific literature necessary for us to conduct our R&D activities," said Michael Trova, Senior Vice President, Drug Discovery. "Investing in the same high-quality information tools on which our customers rely gives them confidence in our expertise and ability to deliver innovative solutions to their projects."
As the winner of Life Science Leader's 2018 CMO Leadership Awards for capabilities, compatibility, expertise, quality, reliability and service, AMRI is dedicated to their clients' success and provides complete capabilities across the entire drug continuum. They have demonstrated innovation success, advancing their clients' programs and products with more than 240 issued patents, 500 peer reviewed publications, and 250 commercial APIs and products in their portfolio.
"CAS values our partnership with AMRI and applauds the innovation successes they have achieved," said Craig Stephens, Chief Customer Officer at CAS. "We appreciate the continued confidence they have placed in SciFinder with this long-term commitment and look forward to helping them continue providing exceptional results to their clients for years to come."